Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith

Patent metadata

Field	Value
Publication number	US-9377463-B2
Application number	US-201414311412-A
Country	US
Kind code	B2
Filing date	Jun 23, 2014
Priority date	May 14, 2008
Publication date	Jun 28, 2016
Grant date	Jun 28, 2016

Abstract

The invention relates to a method for the determination of a cancer diagnostic/therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein/peptide biomarkers and drug-targets based on the measurement of protein/peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein/peptide biomarkers those which show a pronounced differential behavior between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein/peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and selecting as candidate protein/peptide biomarkers those which show a mass-spectrometrically measurable quantitative differential behavior between healthy and cancerous sample proteomes; (c) validation of the candidate protein/peptide biomarkers as identified in step (a), or as optionally verified in step (b), by mass spectrometric measurement and/or antibody-based assays such as an Enzyme-Linked Immunosorbent Assay (ELISA) determination of the candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy human individuals as well as from cancerous human individuals and selecting as protein/peptide biomarkers those which show a mass-spectrometrically measurable and/or antibody-based assay detectable differential behavior between healthy and cancerous sample proteomes; (d) application of statistical methods to uncover single or groups of protein/peptide biomarkers as validated in step (c) as signatures for the detection of patients with cancer. The invention furthermore relates to specific biomarker assays for the highly reliable diagnosis of cancer, specifically of localized or non-localized prostate cancer, using human serum, plasma or any other derivatives of blood, or blood itself.

First claim

The invention claimed is:

1. A method for therapy of prostate cancer of a subject comprising the following steps:
a first step of measuring the concentrations of all of the following three proteins ICAM1, CTSD as well as OLFM4, or in each case fragments thereof in serum, plasma, or blood isolated from the subject, wherein said measuring is performed by contacting the serum, plasma, or blood with an affinity reagent for each protein and detecting whether binding occurs between said proteins and said affinity reagent using a quantitative readout;
a second step of correlating the concentration of said proteins measured in said first step with a predetermined prostate cancer threshold concentration value for each of said proteins; and
a third step of treating said subject wherein the concentration of ICAM1 protein or fragments thereof measured in the first step is less than 340 ng/ml, the concentration of CTSD protein or fragments thereof measured in the first step is less than 32 ng/ml, and the concentration of OLFM4 protein or fragments thereof measured in the first step is less than 20 ng/ml.

2. The method according to claim 1 , wherein said measuring is carried out using at least one technique selected from the group consisting of selected reaction monitoring (SRM), selected reaction monitoring (SRM) in combination with liquid chromatography and enzyme-linked immunosorbent assays (ELISA).

3. The method according to claim 1 , wherein the affinity reagent is an antibody.

4. The method according to claim 1 , wherein the quantitative readout is provided by an enzyme linked immunosorbent assay (ELISA).

5. A method for therapy of localized prostate cancer of a subject comprising the following steps:
a first step of measuring the concentrations of all of the following three proteins ICAM1, CTSD as well as OLFM4, or in each case fragments thereof in serum, plasma, or blood isolated from the subject, wherein said measuring is performed by contacting the serum, plasma, or blood with an affinity reagent for each protein and detecting whether binding occurs between said proteins and said affinity reagent using a quantitative readout;
a second step of correlating the concentration of said proteins measured in said first step with a predetermined localized prostate cancer threshold concentration value for each of said proteins; and
a third step of treating said subject wherein the concentration of ICAM1 protein or fragments thereof measured in the first step is less than 340 ng/ml, the concentration of CTSD protein or fragments thereof measured in the first step is less than 25 ng/ml, and the concentration of OLFM4 protein or fragments thereof measured in the first step is less than 15 ng/ml.

6. The method according to claim 5 , wherein the affinity reagent is an antibody.

7. The method according to claim 5 , wherein the quantitative readout is provided by an enzyme linked immunosorbent assay (ELISA).

8. A method for therapy of localized prostate cancer of a subject involving the following steps:
a first step of measuring the concentrations of all of the following three proteins ICAM1, CTSD as well as OLFM4, or in each case fragments thereof in serum, plasma, or blood isolated from the subject, wherein said measuring is performed by contacting the serum, plasma, or blood with an affinity reagent for each protein and detecting whether binding occurs between said proteins and said affinity reagent using a quantitative readout, and additionally measuring the concentration of the Prostate Specific Antigen (PSA) in the serum, plasma or blood using an affinity reagent-based assay,
a second step of correlating the concentration of said proteins measured in said first step with a predetermined localized prostate cancer threshold concentration value for each of said proteins and correlating the concentration of the Prostate Specific Antigen measured in the affinity reagent-based assay with a predetermined threshold concentration value; and
a third step of treating said subject wherein the concentration of ICAM1 protein or fragments thereof measured in the first step is less than 340 ng/ml, the concentration of CTSD protein or fragments thereof measured in the first step is less than 25 ng/ml, and the concentration of OLFM4 protein or fragments thereof measured in the first step is less than 15 ng/ml.

9. The method according to claim 8 , wherein the affinity reagent is an antibody.

10. The method according to claim 8 , wherein the affinity reagent-based assay is provided by an enzyme linked immunosorbent assay (ELISA).

11. The method according to claim 1 , wherein the first step further comprises measuring the protein concentration of ASPN or fragments thereof so as to measure the protein concentrations of ASPN, ICAM1, CTSD and OLFM4, or in each case fragments thereof.

12. The method according to claim 5 , wherein the first step further comprises measuring the protein concentration of ASPN or fragments thereof so as to measure the protein concentrations of ASPN, ICAM1, CTSD and OLFM4, or in each case fragments thereof.

13. The method according to claim 8 , wherein the first step further comprises measuring the protein concentration of ASPN or fragments thereof so as to measure the protein concentrations of ASPN, ICAM1, CTSD and OLFM4, or in each case fragments thereof.

Assignees

• Eth Zuerich
• St Gallen Kantonsspital

Inventors

• Krek Wilhelm
• Cima Igor
• Aebersold Rudolf
• Schiess Ralph
• Cerny Thomas
• Gillessen Silke

Classifications

• G01N33/57557 Primary

  of other specific parts of the body, e.g. brain · CPC title

• G01N33/57555 Primary

  of the prostate · CPC title

• G01N33/57434 Primary

  Physics · mapped topic

• G01N33/6848

  Methods of protein analysis involving mass spectrometry · CPC title

• G01N33/57407

  Physics · mapped topic